RxSight Q1 revenue $37.9M (+28% YoY); LAL volume up 36%

RxSight, Inc.

2025-Q1 EPS reported -$0.20 revenue$37,895,000

Q1 revenue $37.9M (+28% YoY); LAL revenue +37%, LDD revenue +8%.
Net loss $(8.2M) or $(0.20)/share; adjusted net loss $(1.1M) or $(0.03)/share.
27,579 LALs sold (+36% YoY); 73 LDDs; installed base 1,044 (+43% YoY).
Gross margin 74.8% vs 70.1% YoY; cash $229.3M at quarter end.
Reiterated FY2025 guidance: revenue $160-175M, GM 71-73%, OpEx $150-160M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.